Jiangsu Dinghong Venture Capital Co., Ltd. (Dinghong VC) formally signed an investment agreement with Nantong Molecule Technology Corporation (MTC) days ago. Based on the agreement, Dinghong VC will inject RMB15M into MTC Nantong for expanding the company's production base in Nantong city, and updating its marketing both at home and abroad, to helpMTC Nantong become a lead in China's natural healthcare sector.

MTC Nantong, located in Economic Technology Development Zone in Nantong, Jiangsu province, is a high-tech biopharmaceutical enterprise wholly established by Mr. Xiaozeng Wang who received his PHD degree in the US in 2002. This company specializes in the R&D, production and sales of API intermediates and natural healthcare products. It is the R&D and production base of US-based molecule technology company MTC in China.

After this deal, Dingqiao Venture Capital Management Company, the fund manager of Dinghong VC, will help MTC Nantong become a lead in China's natural healthcare sector, with a goal to go public on domestic growth enterprise market in 2009.